SubjectWell bolsters its global patient recruitment capabilities by acquiring Trials24. The merger combines SubjectWell’s accuracy, diverse patient pool, and predictive capabilities with Trials24’s digital expertise and extensive reach in Europe.
SubjectWell’s Patient Network of over 13 million patients, including 6 million people of color, now gains access to Trials24’s engagement center with native language representatives in over 13 European countries. This collaboration fosters diversity in clinical trials and broadens SubjectWell’s geographic reach.
SubjectWell’s commitment to global healthcare is further strengthened by Trials24’s innovative technology and digital marketing expertise. Together, the companies offer an unparalleled suite of services, including patient engagement, retention, and fulfillment. This integration enables SubjectWell to enhance clinical trial access for patients worldwide.
Trials24 CEO Dr. Tobias Kruse expressed excitement about the merger, stating that their shared vision of improving patient access aligns seamlessly. The combined entity will have the most comprehensive patient reach and engagement centers, supporting global clinical studies.
The integration process is underway, with no disruption to customer or patient engagements anticipated. This strategic alliance promises to revolutionize global patient recruitment, leading to more effective and inclusive clinical research.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
